Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study
- PMID: 11877263
- DOI: 10.1182/blood.v99.6.1938
Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study
Abstract
In a prospective cohort study, we assessed the incidence of spontaneous and risk period-related venous thromboembolism (VTE) in asymptomatic family members of patients who experienced VTE and had the factor V Leiden mutation. In all, 561 family members of 131 probands were included, 313 of whom were carriers (299 heterozygous and 14 homozygous) and 248 of whom were noncarriers of the factor V Leiden mutation. Average follow-up was 4 years (range, 4 months-6 years). There were 1255 and 984 observation-years of follow-up in carriers and noncarriers, respectively. Eight episodes of VTE occurred in heterozygous carriers, resulting in an annual incidence of 0.67% (95% confidence interval [CI], 0.29-1.33). Two events occurred in the absence of associated risk factors, determining an annual incidence of spontaneous VTE of 0.17% (95% CI, 0.02-0.6). Only one VTE (risk period-related) occurred in noncarriers, with an annual incidence of 0.1% (95% CI, 0.003-0.56). Relative risk for VTE in heterozygous carriers compared with noncarriers of the factor V Leiden mutation was 6.6 (95% CI, 1.1-39.8). Risk period-related VTE occurred with an incidence of 18% and 5% per risk period in heterozygous carriers and in noncarriers, respectively. Thus, the low rate of VTE in asymptomatic family members carrying the mutation did not justify continuous anticoagulant prophylaxis. Screening families of symptomatic probands with the factor V Leiden mutation has the potential to identify those asymptomatic carriers who might benefit from thromboprophylaxis during risk periods.
Similar articles
-
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism.Ann Intern Med. 2001 Sep 4;135(5):322-7. doi: 10.7326/0003-4819-135-5-200109040-00008. Ann Intern Med. 2001. PMID: 11529695
-
The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism.Arch Intern Med. 2002 Nov 11;162(20):2357-60. doi: 10.1001/archinte.162.20.2357. Arch Intern Med. 2002. PMID: 12418950
-
Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women.Haematologica. 2001 Dec;86(12):1305-9. Haematologica. 2001. PMID: 11726323
-
Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients?Blood Coagul Fibrinolysis. 2003 Sep;14(6):523-9. doi: 10.1097/00001721-200309000-00002. Blood Coagul Fibrinolysis. 2003. PMID: 12960604
-
Systematic Review and Meta-Analysis of the Susceptibility of ABO Blood Groups to Venous Thromboembolism in Individuals with Factor V Leiden.Diagnostics (Basel). 2022 Aug 11;12(8):1936. doi: 10.3390/diagnostics12081936. Diagnostics (Basel). 2022. PMID: 36010287 Free PMC article. Review.
Cited by
-
Issues concerning the laboratory investigation of inherited thrombophilia.Mol Diagn. 2005;9(4):181-6. doi: 10.1007/BF03260089. Mol Diagn. 2005. PMID: 16392896 Review.
-
VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e691S-e736S. doi: 10.1378/chest.11-2300. Chest. 2012. PMID: 22315276 Free PMC article.
-
Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.J Thromb Thrombolysis. 2016 Jan;41(1):92-128. doi: 10.1007/s11239-015-1309-0. J Thromb Thrombolysis. 2016. PMID: 26780741 Free PMC article.
-
Thrombophilia Testing: from Genetic Predisposition to Discrimination.TH Open. 2024 Apr 8;8(2):e177-e180. doi: 10.1055/a-2284-4285. eCollection 2024 Apr. TH Open. 2024. PMID: 38596262 Free PMC article. No abstract available.
-
A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing.Genet Med. 2016 May;18(5):467-75. doi: 10.1038/gim.2015.104. Epub 2015 Aug 13. Genet Med. 2016. PMID: 26270767 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical